Sarah Ghamrawi

Sarah Ghamrawi is a Clinical Research Associate at Melanoma Institute Australia since December 2022, previously serving as a Research Officer at Children's Cancer Institute from August 2021 to September 2022, where expertise focused on integrating 3D-bioprinting into high-throughput drug screening for neuroblastoma and sarcoma cancers. Prior experience includes a role as a Hospital Scientist at CHU d'Angers from June 2016 to June 2021, where efforts concentrated on developing a hospital platform for ex vivo chemo-sensitivity cell screening and setting up quality control protocols. Additionally, Ghamrawi worked as a Research and Development Engineer at Sociétés d'Accélération du Transfert de Technologies (SATT) - Ouest Valorisation from July 2013 to June 2014, specializing in antimicrobial testing of novel silicones. Educational qualifications include a Doctor of Philosophy (PhD) in Microbiology from Université d'Angers and a Master II Research in Biotechnology, Medical Microbiology from Lebanese University - Faculty of Sciences.